Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors-Reference-Cited by-同舟云学术

Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors

Published:2012-04 Issue:4 Volume:43 Page:489-495
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Dhall Deepti,Mertens Richard,Bresee Catherine,Parakh Rugvedita,Wang Hanlin L.,Li Marissa,Dhall Girish,Colquhoun Steven D.,Ines Delma,Chung Fai,Yu Run,Nissen Nicholas N.,Wolin Edward

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference20 articles.

1. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis;Rindi;Gastroenterol,1999

2. Usefulness of Ki-67 for predicting the metastatic potential of rectal carcinoids;Hotta;Pathol Int,2006

3. The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids: importance of histologic grading, MIB-1, p53, and bcl-2 immunoreactivity;Moyana;Arch Pathol Lab Med,2000

4. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system;Chaudhry;Tumour Biol,1992

5. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors;Strosberg;Hum Pathol,2009

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET;Trials;2024-01-16

2. Neuroendokrine Tumoren;PET/CT-Atlas;2024

3. Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know;Best Practice & Research Clinical Endocrinology & Metabolism;2023-09

4. Potential effective diagnostic biomarker in patients with primary and metastatic small intestinal neuroendocrine tumors;Frontiers in Genetics;2023-04-07

5. Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms;Therapeutic Advances in Medical Oncology;2023-01